Literature DB >> 16781755

GLUT-1-independent infection of the glioblastoma/astroglioma U87 cells by the human T cell leukemia virus type 1.

Qingwen Jin1, Lokesh Agrawal, Zainab Vanhorn-Ali, Ghalib Alkhatib.   

Abstract

The human glucose transporter protein 1 (GLUT-1) functions as a receptor for human T cell leukemia virus (HTLV). GLUT-1 is a twelve-transmembrane cell surface receptor with six extracellular (ECL) and seven intracellular domains. To analyze HTLV-1 cytotropism, we utilized polyclonal antibodies to a synthetic peptide corresponding to the large extracellular domain of GLUT-1. The antibodies caused significant blocking of envelope (Env)-mediated fusion and pseudotyped virus infection of HeLa cells but had no significant effect on infection of U87 cells. This differential effect correlated with the detection of high-level surface expression of GLUT-1 on HeLa cells and very weak staining of U87 cells. To investigate this in terms of viral cytotropism, we cloned GLUT-1 cDNA from U87 cells and isolated two different versions of cDNA clones: the wild-type sequence (encoding 492 residues) and a mutant cDNA with a 5-base pair deletion (GLUT-1Delta5) between nucleotides 1329 and 1333. The deletion, also detected in genomic DNA, resulted in a frame-shift and premature termination producing a truncated protein of 463 residues. Transfection of the wild-type GLUT-1 but not GLUT-1Delta5 cDNA into CHO cells resulted in efficient surface expression of the human GLUT-1. Co-expression of GLUT-1 with GLUT-1Delta5 produces a trans-inhibition by GLUT-1Delta5 of GLUT-1-mediated HTLV-1 envelope (Env)-mediated fusion. Co-immunoprecipitation experiments demonstrated physical interaction of the wild-type and mutant proteins. Northern blot and RT-PCR analyses demonstrated lower GLUT-1 RNA expression in U87 cells. We propose two mechanisms to account for the impaired cell surface expression of GLUT-1 on U87 cells: low GLUT-1 RNA expression and the formation of GLUT-1/GLUT-1Delta5 heterodimers that are retained intracellularly. Significant RNAi-mediated reduction of endogenous GLUT-1 expression impaired HTLV-1 Env-mediated fusion with HeLa cells but not with U87 cells. We propose a GLUT-1-independent mechanism of HTLV-1 infection of U87 cells. The results may have important implications for HTLV-1 neurotropism and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781755     DOI: 10.1016/j.virol.2006.05.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.

Authors:  Heather Keen; Bernd Pichler; Damaris Kukuk; Olivier Duchamp; Olivier Raguin; Aoife Shannon; Nichola Whalley; Vivien Jacobs; Juliana Bales; Neill Gingles; Sally-Ann Ricketts; Stephen R Wedge
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

2.  Preparation, characterization of 2-deoxy-D-glucose functionalized dimercaptosuccinic acid-coated maghemite nanoparticles for targeting tumor cells.

Authors:  Fei Xiong; Zi-yi Zhu; Chen Xiong; Xiao-qing Hua; Xiu-hong Shan; Yu Zhang; Ning Gu
Journal:  Pharm Res       Date:  2011-12-16       Impact factor: 4.200

3.  HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Authors:  Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski; Sébastien Janvier; Nikolaus Heveker; Francis W Ruscetti; Gérard Perret; Kathryn S Jones; Claudine Pique
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

4.  The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Authors:  Kathryn S Jones; Ying K Huang; Sébastien A Chevalier; Philippe V Afonso; Cari Petrow-Sadowski; Daniel C Bertolette; Antoine Gessain; Francis W Ruscetti; Renaud Mahieux
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

5.  Alternate receptor usage of neuropilin-1 and glucose transporter protein 1 by the human T cell leukemia virus type 1.

Authors:  Qingwen Jin; Bashar Alkhatib; Kenneth Cornetta; Ghalib Alkhatib
Journal:  Virology       Date:  2009-11-13       Impact factor: 3.616

Review 6.  Current concepts regarding the HTLV-1 receptor complex.

Authors:  David Ghez; Yves Lepelletier; Kathryn S Jones; Claudine Pique; Olivier Hermine
Journal:  Retrovirology       Date:  2010-11-29       Impact factor: 4.602

Review 7.  Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.

Authors:  Michael D Lairmore; Rajaneesh Anupam; Nadine Bowden; Robyn Haines; Rashade A H Haynes; Lee Ratner; Patrick L Green
Journal:  Viruses       Date:  2011-07-12       Impact factor: 5.048

8.  Cellular Factors Involved in HTLV-1 Entry and Pathogenicit.

Authors:  Hiroo Hoshino
Journal:  Front Microbiol       Date:  2012-06-21       Impact factor: 5.640

9.  Human T-Lymphotropic Virus (HTLV) Type I in vivo Integration in Oral Keratinocytes.

Authors:  Martha C Domínguez; Norma Enith González; Adalberto Sánchez; Felipe García Vallejo
Journal:  Braz J Microbiol       Date:  2011-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.